Stock Analysis on Net
Stock Analysis on Net

AstraZeneca PLC (NYSE:AZN)

This company has been moved to the archive! The financial data has not been updated since March 10, 2015.

Common-Size Income Statement

AstraZeneca PLC, common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Revenue 100.00 100.00 100.00 100.00 100.00
Cost of sales -22.39 -20.46 -19.28 -17.94 -19.20
Gross profit 77.61% 79.54% 80.72% 82.06% 80.80%
Distribution costs -1.24 -1.19 -1.14 -1.03 -1.01
Research and development expense -21.38 -18.75 -18.74 -16.44 -15.98
Selling, general and administrative costs -49.82 -47.47 -35.17 -33.23 -31.40
Profit on disposal of subsidiary 0.00 0.00 0.00 4.41 0.00
Royalties 1.43 1.80 2.03 1.66 1.02
Impairment -0.07 0.00 0.00 0.00 0.00
Net gain (loss) on disposal of non-current assets -0.90 0.05 0.03 0.10 0.20
Gains on disposal of product rights 1.09 0.08 0.91 0.00 0.00
Net loss on disposal of other intangible assets 0.00 0.00 0.00 0.00 0.00
Other income 1.46 0.47 0.50 0.67 0.92
Other expense 0.00 -0.09 0.00 -0.12 0.00
Other operating income and expense 3.02% 2.31% 3.47% 2.31% 2.14%
Operating profit 8.19% 14.44% 29.13% 38.09% 34.55%
Returns on fixed deposits and equity securities 0.04 0.04 0.06 0.03 0.03
Returns on short-term deposits 0.09 0.09 0.09 0.11 0.10
Expected return on post-employment defined benefit plan assets 0.00 0.00 1.74 1.49 1.36
Fair value gains on debt, interest rate swaps and investments 0.06 0.07 0.00 0.01 0.07
Net exchange gains 0.11 0.00 0.00 0.00 0.00
Finance income 0.30% 0.19% 1.89% 1.64% 1.55%
Interest on debt and commercial paper -1.47 -1.51 -1.44 -1.20 -1.35
Interest on overdrafts, finance leases and other financing costs -0.13 -0.10 -0.08 -0.09 -0.09
Net interest on post-employment defined benefit plan net liabilities -0.35 -0.31 -1.81 -1.60 -1.63
Fair value charges on debt, interest rate swaps and investments 0.00 0.00 -0.04 0.00 0.00
Net exchange losses 0.00 -0.01 -0.05 -0.02 -0.03
Discount unwind on contingent consideration arising on business combinations -1.50 0.00 0.00 0.00 0.00
Discount unwind on other long-term liabilities -0.24 0.00 0.00 0.00 0.00
Finance expense -3.69% -1.93% -3.42% -2.92% -3.10%
Share of after tax losses in joint ventures -0.02 0.00 0.00 0.00 0.00
Profit before tax 4.77% 12.71% 27.59% 36.82% 32.99%
Taxation -0.04 -2.71 -4.97 -7.00 -8.70
Profit for the period 4.73% 10.00% 22.62% 29.82% 24.29%
Profit attributable to non-controlling interests -0.01 -0.06 -0.11 -0.10 -0.08
Profit attributable to owners of the Parent 4.73% 9.94% 22.51% 29.72% 24.21%

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Income statement item Description The company
Operating profit The net result for the period of deducting operating expenses from operating revenues. AstraZeneca PLC operating profit as a percentage of revenue decreased from 2012 to 2013 and from 2013 to 2014.
Profit before tax Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. AstraZeneca PLC profit before tax as a percentage of revenue decreased from 2012 to 2013 and from 2013 to 2014.
Profit attributable to owners of the Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. AstraZeneca PLC profit attributable to owners of the Parent as a percentage of revenue decreased from 2012 to 2013 and from 2013 to 2014.